DESTINY-Breast09 aims to bring Enhertu to the first-line metastatic setting with both monotherapy and pertuzumab combination ... are not fulfilled at the pharmacy level because still of access ...

Furthermore, in oncology, Perjeta/Phesgo conversion rate is now ... exchange rates and that was driven by a large specialty pharmacy order, which is very similar to the pattern that we've seen ...

AZN earnings call for the period ending December 31, 2024.

New Zealand women with ovarian cancer finally have funded access to bevacizumab. Pharmac’s announcement yesterday comes ten years after the treatment was funded in Australia, and follows a long ...

Darzalex & Darzalex Faspro are indicated for the treatment of multiple myeloma. Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with ...

On February 2, 2025, Shanghai Henlius Biotech, Inc. (“Henlius”) announced FDA acceptance of the Biologics License Application (BLA) for HLX11, a proposed biosimilar to Genentech’s PERJETA.

Roche reported robust financial performance for the fourth quarter of 2024, with significant growth in both sales and core operating profit. The company's strategic focus on innovation and ...

The healthcare industry experienced a rollercoaster of a year in 2024, with pharmacy benefits undergoing significant shifts. Rising drug costs, advancements in medication technology, and changing ...

Good morning to those joining from the U.K. and the U.S. Good afternoon to those in Central Europe, and good evening to those listening in Asia. Welcome, ladies and gentlemen, to AstraZeneca's ...

Despite the impact of the pandemic on cancer care, Perjeta grew 17% to CHF 2.9 billion ($3.2 billion) in the first nine months of 2020, now just fractionally behind Herceptin which declined 31% to ...

Pharmac is reconsidering its decision to fund only one brand of HRT oestrogen patches after receiving considerable feedback. The patches are used by menopausal people as a hormone replacement therapy ...